Cargando…
Systemic Outcomes of Intravitreal Injections of Dexamethasone and Anti-Vascular Endothelial Growth Factor
INTRODUCTION: Intravitreal dexamethasone and anti-vascular endothelial growth factor (anti-VEGF) medications have revolutionized ocular disease management and favorable ocular safety profiles, but few studies have compared their systemic adverse events (SAEs). This study investigated the SAEs of int...
Autores principales: | Lin, Tzu-Yi, Hsieh, Yi-Ting, Garg, Sunir J., Chen, Lee-Jen, Chen, Kuan-Jen, Wu, Wei-Chi, Lai, Chi-Chun, Hwang, Yih-Shiou, Kang, Eugene Yu-Chuan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10011242/ https://www.ncbi.nlm.nih.gov/pubmed/36729247 http://dx.doi.org/10.1007/s40123-023-00659-3 |
Ejemplares similares
-
The Association of Intravitreal Injections of Different Anti-Vascular Endothelial Growth Factor with Systemic Outcomes in Diabetic Patients
por: Kang, Eugene Yu-Chuan, et al.
Publicado: (2023) -
Intravitreal Dexamethasone Implants for Refractory Macular Edema in Eyes with Noninfectious Uveitis
por: Kang, Eugene Yu-Chuan, et al.
Publicado: (2021) -
Risk of Diabetic Retinopathy between Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists
por: Lin, Tzu-Yi, et al.
Publicado: (2023) -
Analysis of aqueous humor total antioxidant capacity and its correlation with corneal endothelial health
por: Tsao, Yu‐Ting, et al.
Publicado: (2020) -
Short-term efficacy of intravitreal Aflibercept injections for retinal angiomatous proliferation
por: Chou, Hung-Da, et al.
Publicado: (2017)